Characterization of the 16+9 kb and 30+9 kb CYP2D6 XbaI haplotypes

Pharmacogenetics

Volumn 7, Issue 2, 1997, Pages 149-152

  Løvlie, Roger ^a   Daly, Ann K ^b   Idle, Jeffrey R ^c   Steen, Vidar M ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

CYP2D6 genotyping; Debrisoquine 4 hydroxylase; Poor metabolizer; Ultrarapid metabolizer

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE; OXYGENASE;

ALLELE; ARTICLE; CHROMOSOME 22Q; DNA DETERMINATION; DNA SEQUENCE; DRUG METABOLISM; HAPLOTYPE; HUMAN; PRIORITY JOURNAL; PSEUDOGENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AFRICA, NORTHERN; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; HAPLOTYPES; HUMANS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0030938177     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199704000-00009     Document Type: Article

References (22)

1. Agundez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP 2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995: 57, 265-269.
2. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991: 10, 545-558.
3. Brosen K, Gram LE. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989: 36, 537-547.
4. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995: 274, 516-520.
5. Daly AK, London SJ, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991: 1, 33-41.
6. Daly AK, Fairbrother KS, Andreassen OA, Armstrong M, Idle JR, Steen VM. Characterization and PCR-based detection of two different hybrid CYP2D7/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetic 1996a: 6, 319-328.
7. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996b: 6, 193-201.
8. Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multiallelism. Methods Enzymol 1996c: 272, 199-210.
9. Eichelbaum M, Baur MP, Osikowska-Evers BO, Tieves G, Zekorn C, Rittner C. Chromosomal assignment of human cytochrome P450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 1987: 23, 455-458.
10. Evans DA, Maghoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxydation in a white British population. J Med Genet 1980: 17, 102-105.
11. Evans WE, Relling MV, Xba 1 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquine hydroxylase: report of a family study. Mol Pharmacol 1990: 37, 639-642.
12. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991: 48, 943-950.
13. Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, Gelboin HV, Meyer UA. Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 1988: 2, 174-179.
14. Heim M, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992: 14, 49-58.
15. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90, 11825-11829.
16. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 1989: 45, 889-904.
17. Kroemer HK, Eichelbaum M. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995: 56, 2285-2298.
18. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Letters 1996: 392, 30-34.
19. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993: 3, 275-280.
20. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988: 85, 5240-5243.
21. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen A-L, Idle JR, Gulbrandsen A-K. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995a: 5, 215-223.
22. Steen VM, Molven A, Aarskog NK, Gulbrandsen A-K. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of the human cytochrome P450 CYP2D6 gene. Hum Mol Genet 1995b: 4, 2251-2257.